Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

July 31, 2009

Conditions
Esophageal Cancer
Interventions
BIOLOGICAL

URLC10

Biological: URC10 Patients will be vaccinated once in one week to the eighth vaccine and will be vaccinated once in two weeks from the ninth vaccine. On each vaccination day, the URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by endodermic injection.

Trial Locations (1)

589-8511

department of surgery, Kinki University, Sayama

All Listed Sponsors
collaborator

Human Genome Center, Institute of Medical Science, University of Tokyo

OTHER

lead

Kinki University

OTHER

NCT00753844 - Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer | Biotech Hunter | Biotech Hunter